In the News
Caribou Bioscience’s CEO on CRISPR’s legal and ethical challenges
Caribou Bioscience co-founder and CEO Rachel Haurwitz joined us onstage at Disrupt this morning to help unpack some of the myriad complexities around her company’s pioneering work in the field of CRISPR biology. The gene editing tool has been the source of tremendous excitement over the last several years for its potential to help science hack everything from disease to food supply.
Nature Biotechnology First Rounders Podcast
Rachel Haurwitz is co-founder, president and CEO of Caribou Biosciences. In her discussion with Nature Biotechnology, she explains what drew her into the sciences, how her father's journalism career brought their family to Austin, Texas, and how she found herself at the cutting edge of CRISPR technology.
Researchers Publish Two New Methods for Analysis of CRISPR Off-Target Effects
Two studies published simultaneously in Nature Methods yesterday describe new methods for analyzing the off-target effects of CRISPR/Cas-9 genome editing. One method identifies off-target mutations associated with cell-type-specific SNPs, while the other detects potential off-target cleavage sites.
From corn to cattle, gene editing is about to supercharge agriculture
Corn isn’t the sexiest crop but it’s one of the most important. It’s the most abundant grain on Earth, used as food and biofuel around the globe. In ancient times, Mesoamericans thrived on it, waged wars over it. Their myths claimed corn was the matter from which gods created mankind itself.
Edit your future with a career in CRISPR
Some early-career scientists found themselves surfing the wave of CRISPR just as it hit the shore.